Part1: Placebo

BIOLOGICAL2 trials

Sponsors

Jiangsu Rec-Biotechnology Co., Ltd., Zhuhai United Laboratories Co., Ltd.

Conditions

COVID-19Paroxysmal Nocturnal Hemoglobinuria, PNH

Phase 1

To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.

RecruitingNCT07760467

Zhuhai United Laboratories Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria, PNH

Start: 2026-08-26End: 2027-05-08Target: 94Updated: 2026-09-01

Phase 2

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)

CompletedNCT05084989

Jiangsu Rec-Biotechnology Co., Ltd.COVID-19

Start: 2022-01-31End: 2023-02-09Updated: 2024-02-29

Related Papers

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Expert Review of Vaccines2024-03-26

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies

Infectious Diseases and Therapy2023-12-161 citations